Issue link: https://www.e-digitaleditions.com/i/1500880
This section provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. 20 June 2023 Inhalation ISSUE FOCUS Nasal Delivery, Nebulizers and Soft Mist Inhalers This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No product endorsement or preference is intended. Benchtop environmental chamber Take control of your OIP testing with our bench- top environmental chamber, EnviroMate™. Provid- ing robust control of temperature, relative humidity and electrostatic charge, EnviroMate delivers con- sistent environmental control within the immediate test area. Interfacing seamlessly with both the NGI Cooler™ and Breathing Simulator BRS 200i, Enviro- Mate helps enhance data accuracy and repeatability for inhaled products such as nebulizers and SMIs/ ADIs, whose performance are known to be partic- ularly sensitive to environmental conditions. Learn more: https://bit.ly/EnviroMate. Copley Scientific UK: +44 1159 616229 sales@copleyscientific.co.uk www.copleyscientific.com Integrated development and manufacturing services Recipharm offers integrated service for developing, customizing and manufacturing drug/device com- binations throughout the product lifecycle, includ- ing our Resyca ® Pulmospray™ and PFSI™ soft mist inhalers. Our inhalers use Medspray's proprietary micro-nozzle technology to nebulize APIs into a fine mist, ensuring droplet size distribution is uni- form and highly sensitive APIs reach the patient's deep lung without degradation. Services for soft mist inhalation range from early-stage development to commercial manufacture. Discover how we develop patient- centered inhalation treatments that improve patients' quality of life and comfort. Recipharm UK: +44 1553 691000 www.recipharm.com Powder characterization for nasal formulations Lonza's Small Molecules division has provided inte- grated inhaled dry powder development services for more than 25 years. In response to the increasing complexity of molecules in the pipeline, we recently enhanced our powder characterization capabilities at our Tampa, Florida, US site. e addition of uni- versal powder flow testing and automated particle size and shape analysis systems can enable greater understanding of the behavior of powdered drug substances and, in turn, optimize drug product for- mulations for our customers. Lonza Small Molecules US: +1 813 286-0404 small.molecules@lonza.com www.lonza.com